Biotherapy Services

Biotherapy Services is a private, clinical-stage biotech firm developing autologous biological therapies for wound healing, particularly diabetic foot ulcers and pressure sores. Its core asset is the RAPID™ Biodynamic Haematogel, a patient-specific gel that concentrates platelets and growth factors to stimulate the body's natural healing processes. The company is currently conducting a Phase 2/3 clinical trial (RAPID-1DFU) at multiple UK hospital sites and operates under GMP manufacturing standards. Founded in 2012, it represents a specialized player in the advanced wound care and regenerative medicine sector.

Patented process for creating autologous, blood-derived biodynamic gels. Concentrates patient's own platelets and white blood cells, activates them with autologous thrombin to release a cocktail of healing growth factors and signaling proteins for localized, point-of-care application.

Biotherapy Services competes in the advanced wound care market against large medical device companies (e.g., Smith & Nephew, Mölnlycke, ConvaTec) offering advanced dressings, negative pressure therapy, and skin substitutes, as well as other biotech firms developing growth factor therapies and allogeneic cell treatments. Its key differentiation is its status as a first-in-class, autologous, point-of-care medicine.